James E. Dentzer - 04 Aug 2025 Form 4 Insider Report for Imunon, Inc. (IMNN)

Reporting relationship: Director
Issuer ticker: IMNN
Reported as of: 04 Aug 2025
Net transaction value: +$30,526
SEC form: 4
Accepted by SEC: 06 Aug 2025, 16:37:44 UTC
Prior SEC filing: 22 May 2025
Next SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Susan Eylward, Attorney-in-Fact for James E. Dentzer

Key filing fact

James E. Dentzer filed Form 4 for Imunon, Inc. (IMNN) on 06 Aug 2025.

Key facts

This page summarizes James E. Dentzer's Form 4 filing for Imunon, Inc. (IMNN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Aug 2025, 16:37.

Change

Previous filing in this sequence was filed on 22 May 2025.
Current net transaction value: +$30,526.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001400977 Primary reporting owner

Dentzer James E

Relationship: Director
Address: C/O IMUNON, INC., 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE
Signature: /s/ Susan Eylward, Attorney-in-Fact for James E. Dentzer
Signature date: 06 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMNN transaction

Common Stock

Award

Transaction value: $30,526
Shares: +3,318
Change %
Price: $9.20
Shares after: 3,318
Date: 04 Aug 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMNN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +250
Change %
Price: $0.000000
Shares after: 250
Date: 04 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250
Exercise price: $9.20
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Stock granted in lieu of cash for portion of board fees

Footnote F2

Represents the closing price of Imunon, Inc. Common Stock on the date of grant.

Footnote F3

The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

SEC remarks

On July 25, 2025, the Issuer effected a reverse stock split of Issuer Common Stock at a ratio of 1-for-15 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the shares of Issuer Common Stock, and the exercise price and shares of Issuer Common Stock underlying outstanding equity awards, have been adjusted accordingly versus any amounts previously reported by the Reporting Person.